BEONE MEDICINES 1H Net Profit Swells 386% to USD464M; Full-year Revenue and Earnings Guidance Raised; US Premarket Up ~4%AASTOCKS News·11 hours agoBGNE0.00%ONC+1.40%
BeOne Medicines Posts Unaudited Q2 2026 Results and Cautions on Preliminary GuidanceTip Ranks·11 hours agoONC+1.40%BGNE0.00%
BeOne Medicines: Q2 2026 revenue up 30% to $1.7B, net income up 151%, driven by strong product sales and margin gainsQuartr·11 hours agoBGNE0.00%ONC+1.40%
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM06160+2.63%BGNE0.00%
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform RatingAASTOCKS News·Jul 13 at 03:20 AMONC+1.40%06160+2.63%
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline ProgressTip Ranks·Jul 12 at 07:25 PM06160+2.63%688235+7.12%
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)Tip Ranks·Jul 7 at 12:15 AMONC+1.40%BGNE0.00%
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma | ONC Stock NewsStockTitan·Jun 29 at 09:00 PMONC+1.40%BGNE0.00%
BeOne Medicines Chief Executive Officer Sold Shares Worth Over $933KTradingView·Jun 25 at 04:20 PM688235+7.12%ONC+1.40%
BeOne Medicines Executives Quietly Cash In on a Wave of Insider Stock SalesTip Ranks·Jun 18 at 09:06 PMONC+1.40%688235+7.12%
BeOne Medicines Chief Executive Officer Sold Shares Worth Over $980KTradingView·Jun 18 at 04:20 PMBGNE0.00%06160+2.63%
BeOne Medicines Grants New Equity Awards Under 2016 Incentive PlanTip Ranks·Jun 18 at 08:46 AMBGNE0.00%06160+2.63%
